Vise Technologies Inc. Buys 3,580 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Vise Technologies Inc. increased its stake in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 195.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,407 shares of the company's stock after buying an additional 3,580 shares during the quarter. Vise Technologies Inc.'s holdings in HCA Healthcare were worth $1,623,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Whipplewood Advisors LLC purchased a new stake in shares of HCA Healthcare during the fourth quarter worth about $31,000. Tidemark LLC purchased a new stake in shares of HCA Healthcare during the fourth quarter worth approximately $36,000. Activest Wealth Management grew its holdings in HCA Healthcare by 1,250.0% in the 4th quarter. Activest Wealth Management now owns 135 shares of the company's stock valued at $40,000 after buying an additional 125 shares in the last quarter. Legacy Investment Solutions LLC lifted its stake in shares of HCA Healthcare by 99.0% in the 4th quarter. Legacy Investment Solutions LLC now owns 191 shares of the company's stock valued at $62,000 after purchasing an additional 95 shares during the last quarter. Finally, Physician Wealth Advisors Inc. acquired a new position in shares of HCA Healthcare in the 4th quarter valued at $64,000. 62.73% of the stock is currently owned by institutional investors.

HCA Healthcare Stock Performance

NYSE:HCA traded up $2.53 during trading hours on Thursday, reaching $380.97. 425,959 shares of the stock were exchanged, compared to its average volume of 1,436,492. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07. The firm has a 50 day simple moving average of $349.48 and a 200-day simple moving average of $329.96. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $417.14. The stock has a market capitalization of $91.65 billion, a P/E ratio of 17.34, a P/E/G ratio of 1.10 and a beta of 1.46.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its quarterly earnings results on Friday, April 25th. The company reported $6.45 earnings per share for the quarter, topping analysts' consensus estimates of $5.75 by $0.70. The business had revenue of $18.32 billion for the quarter, compared to analysts' expectations of $18.26 billion. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. The business's quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $5.36 EPS. As a group, sell-side analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 16th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.76%. The ex-dividend date is Monday, June 16th. HCA Healthcare's dividend payout ratio is currently 12.81%.

Insider Buying and Selling at HCA Healthcare

In other news, COO Jon M. Foster sold 15,698 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $369.32, for a total transaction of $5,797,585.36. Following the completion of the sale, the chief operating officer now directly owns 12,646 shares of the company's stock, valued at $4,670,420.72. This trade represents a 55.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HCA shares. Baird R W cut HCA Healthcare from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 15th. Robert W. Baird reissued a "neutral" rating and set a $336.00 target price (down previously from $396.00) on shares of HCA Healthcare in a research report on Tuesday, April 15th. Guggenheim started coverage on HCA Healthcare in a research report on Wednesday, April 9th. They set a "neutral" rating on the stock. Wall Street Zen raised HCA Healthcare from a "hold" rating to a "buy" rating in a report on Monday, April 28th. Finally, Royal Bank of Canada decreased their target price on HCA Healthcare from $384.00 to $376.00 and set an "outperform" rating on the stock in a research report on Monday, April 28th. Seven research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $385.47.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.